Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Genmab's Phase 3 RAINFOL-02 trial of Rina-S in platinum-resistant ovarian cancer met its primary endpoint of progression-free survival and its key secondary endpoint of overall survival versus investigator's choice chemotherapy. In the intent-to-treat population (N=584), Rina-S cut the risk of progression or death by 71% (HR 0.29, p<0.0001) and the risk of death by 57% (OS HR 0.43), regardless of FRα expression or prior mirvetuximab treatment, with no new safety signals.
Key figures
- Drug Name
- rinatabart sesutecan (Rina-S; GEN1184)
- Phase Of Trial
- Phase 3
- Itt population n
- 584
- Pas population n
- 492
- Os hazard ratio itt
- 0.43
- Os hazard ratio pas
- 0.44
- Pfs hazard ratio itt
- 0.29
- Pfs hazard ratio pas
- 0.33
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.